La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Repare Therapeutics Croissance future
Future contrôle des critères 1/6
Les bénéfices de Repare Therapeutics devraient diminuer de 19.8% par an tandis que son chiffre d'affaires annuel devrait croître de 13.1% par an. Le BPA devrait croître de diminuer de 11.4% par an. Le rendement des capitaux propres devrait être -56.9% dans 3 ans.
Informations clés
-19.8%
Taux de croissance des bénéfices
-11.4%
Taux de croissance du BPA
Biotechs croissance des bénéfices | 30.3% |
Taux de croissance des recettes | 13.1% |
Rendement futur des capitaux propres | -56.9% |
Couverture par les analystes | Good |
Dernière mise à jour | 19 Aug 2024 |
Mises à jour récentes de la croissance future
Recent updates
Will Repare Therapeutics (NASDAQ:RPTX) Spend Its Cash Wisely?
Jul 12Repare Therapeutics Inc.'s (NASDAQ:RPTX) 34% Dip In Price Shows Sentiment Is Matching Revenues
May 01Benign Growth For Repare Therapeutics Inc. (NASDAQ:RPTX) Underpins Stock's 30% Plummet
Mar 12We Think Repare Therapeutics (NASDAQ:RPTX) Needs To Drive Business Growth Carefully
Feb 15Repare Therapeutics Inc. (NASDAQ:RPTX) Shares Fly 30% But Investors Aren't Buying For Growth
Dec 20Here's Why We're Not At All Concerned With Repare Therapeutics' (NASDAQ:RPTX) Cash Burn Situation
Oct 24New Forecasts: Here's What Analysts Think The Future Holds For Repare Therapeutics Inc. (NASDAQ:RPTX)
Aug 14Analysts Are Betting On Repare Therapeutics Inc. (NASDAQ:RPTX) With A Big Upgrade This Week
May 14Analysts Are Upgrading Repare Therapeutics Inc. (NASDAQ:RPTX) After Its Latest Results
May 12Repare Therapeutics Inc. (NASDAQ:RPTX) Looks Inexpensive But Perhaps Not Attractive Enough
May 08Growth Investors: Industry Analysts Just Upgraded Their Repare Therapeutics Inc. (NASDAQ:RPTX) Revenue Forecasts By 31%
Mar 03Companies Like Repare Therapeutics (NASDAQ:RPTX) Are In A Position To Invest In Growth
Oct 27Repare Therapeutics: Budding Synthetic Lethality Player With 3 Big Pharma Partners
Sep 07Repare Therapeutics GAAP EPS of -$0.91 misses by $0.06, revenue of $0.67M
Aug 04Repare Therapeutics: Interesting Gene Editing Company, But Miles To Go
Jun 27Companies Like Repare Therapeutics (NASDAQ:RPTX) Are In A Position To Invest In Growth
Jun 24Repare Therapeutics (NASDAQ:RPTX) Is In A Good Position To Deliver On Growth Plans
Mar 02We're Not Worried About Repare Therapeutics' (NASDAQ:RPTX) Cash Burn
Oct 14We Think Repare Therapeutics (NASDAQ:RPTX) Can Easily Afford To Drive Business Growth
Apr 16Have Repare Therapeutics Inc. (NASDAQ:RPTX) Insiders Been Selling Their Stock?
Mar 12Are Institutions Heavily Invested In Repare Therapeutics Inc.'s (NASDAQ:RPTX) Shares?
Feb 08Repare Therapeutics: CRISPR-Enabled Technology Might Unlock New Therapies
Dec 28Trade Alert: The Executive VP & Head of Business & Corporate Development Of Repare Therapeutics Inc. (NASDAQ:RPTX), Kim Seth, Has Sold Some Shares Recently
Dec 21We Think Repare Therapeutics (NASDAQ:RPTX) Can Easily Afford To Drive Business Growth
Nov 19Prévisions de croissance des bénéfices et des revenus
Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
---|---|---|---|---|---|
12/31/2026 | 40 | -154 | -138 | -133 | 6 |
12/31/2025 | 12 | -166 | -126 | -125 | 7 |
12/31/2024 | 59 | -100 | -65 | -65 | 8 |
6/30/2024 | 69 | -69 | -80 | -80 | N/A |
3/31/2024 | 98 | -46 | -85 | -83 | N/A |
12/31/2023 | 51 | -94 | -129 | -127 | N/A |
9/30/2023 | 56 | -97 | -128 | -129 | N/A |
6/30/2023 | 167 | -3 | -8 | -8 | N/A |
3/31/2023 | 137 | -29 | -2 | -1 | N/A |
12/31/2022 | 132 | -29 | 0 | 0 | N/A |
9/30/2022 | 121 | -26 | 7 | 9 | N/A |
6/30/2022 | 8 | -132 | -114 | -112 | N/A |
3/31/2022 | 8 | -120 | -103 | -102 | N/A |
12/31/2021 | 8 | -107 | -87 | -86 | N/A |
9/30/2021 | 1 | -94 | -81 | -78 | N/A |
6/30/2021 | 1 | -77 | -69 | -65 | N/A |
3/31/2021 | 0 | -62 | -14 | -11 | N/A |
12/31/2020 | 0 | -53 | -8 | -6 | N/A |
9/30/2020 | N/A | -46 | -4 | -2 | N/A |
6/30/2020 | N/A | -40 | 11 | 12 | N/A |
3/31/2020 | N/A | -35 | -32 | -31 | N/A |
12/31/2019 | N/A | -27 | -20 | -18 | N/A |
12/31/2018 | N/A | -14 | -13 | -13 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: RPTX devrait rester non rentable au cours des 3 prochaines années.
Bénéfices vs marché: RPTX devrait rester non rentable au cours des 3 prochaines années.
Croissance élevée des bénéfices: RPTX devrait rester non rentable au cours des 3 prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de RPTX ( 13.1% par an) devrait croître plus rapidement que le marché US ( 8.8% par an).
Croissance élevée des revenus: Le chiffre d'affaires de RPTX ( 13.1% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: RPTX devrait être non rentable dans 3 ans.